The management of lymphoma in the immunosuppressed patient

Best Practice & Research Clinical Haematology - Tập 15 - Trang 517-532 - 2002
Mark Bower1
1Department of Oncology, Chelsea & Westminster Hospital, Fulham Road, London, SW10 9NH, UK

Tài liệu tham khảo

Ziegler, 1984, Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome, New England Journal of Medicine, 311, 565, 10.1056/NEJM198408303110904

Opelz, 1993, Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients, Lancet, 342, 1514, 10.1016/S0140-6736(05)80084-4

Gross, 1999, B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome, Bone and Marrow Transplantation, 23, 251, 10.1038/sj.bmt.1701554

Ohga, 2000, Epstein–Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond–Blackfan anemia, Bone and Marrow Transplantation, 25, 209, 10.1038/sj.bmt.1702138

Shapiro, 1988, Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation, Blood, 71, 1234, 10.1182/blood.V71.5.1234.1234

Armes, 1994, Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation, Cancer, 74, 2436, 10.1002/1097-0142(19941101)74:9<2436::AID-CNCR2820740908>3.0.CO;2-S

Strazzabosco, 1997, Epstein–Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients, Journal of Hepatology, 26, 926, 10.1016/S0168-8278(97)80262-0

Swinnen, 1990, Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients, New England Journal of Medicine, 323, 1723, 10.1056/NEJM199012203232502

Walker, 1995, Pretransplantation assessment of the risk of lymphoproliferative disorder, Clinical Infectious Diseases, 20, 1346, 10.1093/clinids/20.5.1346

Ellis, 1999, Epstein–Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression, Transplantation, 68, 997, 10.1097/00007890-199910150-00017

Shapiro, 1999, Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression, Transplantation, 68, 1851, 10.1097/00007890-199912270-00006

Hezode, 1999, Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation, Hepatology, 30, 775, 10.1002/hep.510300314

Knowles, 1995, Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders, Blood, 85, 552, 10.1182/blood.V85.2.552.552

Hanson, 1996, Posttransplant T-cell lymphoproliferative disorders--an aggressive, late complication of solid-organ transplantation, Blood, 88, 3626, 10.1182/blood.V88.9.3626.bloodjournal8893626

Cesarman, 1998, BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome, Blood, 92, 2294, 10.1182/blood.V92.7.2294

Darenkov, 1997, Reduced incidence of Epstein–Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy, Transplantation, 64, 848, 10.1097/00007890-199709270-00010

Rowe, 1997, Use of quantitative competitive PCR to measure Epstein–Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders, Journal of Clinical Microbiology, 35, 1612, 10.1128/JCM.35.6.1612-1615.1997

Stevens, 1999, Monitoring of Epstein–Barr virus DNA load in peripheral blood by quantitative competitive PCR, Journal of Clinical Microbiology, 37, 2852, 10.1128/JCM.37.9.2852-2857.1999

Limaye, 1999, Detection of Epstein–Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders, Journal of Clinical Microbiology, 37, 1113, 10.1128/JCM.37.4.1113-1116.1999

Nalesnik, 1988, The diagnosis and treatment of posttransplant lymphoproliferative disorders, Current Problems in Surgery, 25, 367, 10.1016/0011-3840(88)90011-1

Hanto, 1982, Epstein–Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation, New England Journal of Medicine, 306, 913, 10.1056/NEJM198204153061506

O'Brien, 1997, Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy, Journal of the American Society of Nephrology, 8, 1483, 10.1681/ASN.V891483

Benkerrou, 1998, Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome, Blood, 92, 3137, 10.1182/blood.V92.9.3137

Gross, 1998, Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy, Annals of Oncology, 9, 339, 10.1023/A:1008263226895

Heslop, 1994, Donor T cells to treat EBV-associated lymphoma, New England Journal of Medicine, 331, 679, 10.1056/NEJM199409083311017

Rooney, 1995, Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation, Lancet, 345, 9, 10.1016/S0140-6736(95)91150-2

Rooney, 1998, Immunotherapy for Epstein–Barr virus-associated cancers, Journal of National Cancer Institute Monographs, 23, 89, 10.1093/oxfordjournals.jncimonographs.a024180

Savoldo, 2001, Generation of autologous Epstein–Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients, Transplantation, 72, 1078, 10.1097/00007890-200109270-00017

Papadopoulos, 1994, Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation, New England Journal of Medicine, 330, 1185, 10.1056/NEJM199404283301703

Nalesnik, 1997, Autologous lymphokine-activated killer cell therapy of Epstein–Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients, Transplantation, 63, 1200, 10.1097/00007890-199705150-00002

Emanuel, 1997, Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes, Transplantation, 63, 1691, 10.1097/00007890-199706150-00027

2000, Journal of the National Cancer Institute, 92, 1823, 10.1093/jnci/92.22.1823

Nador, 1996, Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus, Blood, 88, 645, 10.1182/blood.V88.2.645.bloodjournal882645

Schnittman, 1986, Direct polyclonal activation of human B lymphocytes by the AIDS virus, Science, 233, 1084, 10.1126/science.3016902

Kersten, 1998, Expression of Epstein--Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphoma: correlation with histology and CD4 cell number, Leukemia & Lymphoma, 30, 515, 10.3109/10428199809057564

Gaidano, 1999, BCL-6 in AIDS-related lymphomas: pathogenetic and histogenetic implications, Leukemia & Lymphoma, 31, 39, 10.3109/10428199809057583

Gaidano, 2000, Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas, Genes, Chromosomes and Cancer, 27, 177, 10.1002/(SICI)1098-2264(200002)27:2<177::AID-GCC9>3.0.CO;2-O

Benmiloud, 1999, Results using chemotherapy in AIDS patients with hepatic non-Hodgkin's lymphoma (HNHL), Proceedings of the American Society of Clinical Oncology, 18, 12a

Levine, 1991, Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma, Journal of the American Medical Association, 266, 84, 10.1001/jama.266.1.84

Kaplan, 1995, Randomized trial of standard dose mBACOD with GM-CSF vs. reduced dose mBACOD for systemic HIV-associated lymphoma: ACTG 142, Proceedings of the American Society of Clinical Oncology, 14, 288

Tirelli, 2000, Dose adjusted treatment in AIDS-related lymphoma, Journal of the Acquired Immunodeficiency Syndrome, 23, A12

Chow, 2001, Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART), Leukemia & Lymphoma, 41, 105, 10.3109/10428190109057959

Navarro, 2001, Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone, British Journal of Haematology, 112, 909, 10.1046/j.1365-2141.2001.02656.x

Sparano, 1996, Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV associated non-Hodgkin's lymphoma, Journal of Clinical Oncology, 14, 3026, 10.1200/JCO.1996.14.11.3026

Sparano, 2000, Infusional cyclophosphamide, doxorubicin and etoposide in HIV associated non-Hodgkin's lymphoma: a review of the Einstein, Aviano and ECOG experience in 182 patients, Journal of AIDS, 23, A11

Little, 1999, Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma, Proceedings of the American Society of Clinical Oncology, 18, 10a

Douek, 1998, Changes in thymic function with age and during the treatment of HIV infection, Nature, 396, 690, 10.1038/25374

Mackall, 1996, Thymic-independent T cell regeneration occurs via antigen driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing, Journal of Immunology, 156, 4609, 10.4049/jimmunol.156.12.4609

Zanussi, 1996, The effects of antineoplastic chemotherapy on HIV disease, AIDS Research and Human Retroviruses, 12, 1703, 10.1089/aid.1996.12.1703

Powles, 2002, The effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV associated lymphoma, AIDS, 10.1097/00002030-200203080-00003

Levine, 1997, Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial, Journal of Clinical Oncology, 15, 1094, 10.1200/JCO.1997.15.3.1094

Levine, 2000, Treatment of relapsed/refractory AIDS related lymphomas with high dose cytarabine/cisplatin combination regimens, Journal of the Acquired Immunodeficiency Syndrome, 23, A24

Arribas, 1995, Detection of Epstein–Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma, Journal of Clinical Microbiology, 33, 1580, 10.1128/JCM.33.6.1580-1583.1995

De Luca, 1995, Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma, British Journal of Haematology, 90, 844, 10.1111/j.1365-2141.1995.tb05205.x

Castagna, 1997, Evaluation of contrast-enhancing brain lesions in AIDS patietns by means of Epstein–Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography, AIDS, 11, 1522

Jacomet, 1997, Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS, AIDS, 11, 1725, 10.1097/00002030-199714000-00009